Cost-effectiveness of sentinel lymph node biopsy in thin melanomas

Surgery

Volumn 134, Issue 4, 2003, Pages 542-547

  Agnese, Doreen M ^a   Abdessalam, Shahab F ^a   Burak Jr , William E ^a   Magro, Cynthia M ^a   Pozderac, Rodney V ^a   Walker, Michael J ^a   Velasco, Jose M ^b   Aranha, Gerard V ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b Doan N908 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SENTINEL LYMPH NODE;

EID: 0242550923     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(03)00275-7     Document Type: Article

References (23)

1. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C. Multi-institutional melanoma lymphatic mapping experience: the prognostic status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17: 976-83.
2. Balch CM, Buzaid AC, Seng-Jaw S, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy in high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
4. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Niewig OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg 1999;230:453-63.
5. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma. Ann Surg Oncol 2000;7:160-5.
6. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumor thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg 2002;89:1223-7.
7. Nguyen CL, McClay EF, Cole DJ, O'Brien PH, Gillanders WE, Metcalf JS, et al. Melanoma thickness and histology predict sentinel lymph node status. Am J Surg 2001;181: 8-11.
8. Kelly JW, Sagebiel RW, Clyman S, Blois MS. Thin level IV malignant melanoma. A subset in which level is the major prognostic indicator. Ann Surg 1985;202:98-103.
9. Corsetti RL, Allen HM, Wanebo HJ. Thin ≤1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 2000;7:456-60.
10. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reitngen DS, Cascinelli N. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
11. Shaw HM, McCarthy WH, McCarthy SW, Milton GW. Thin malignant melanomas and recurrence potential. Arch Surg 1987;122:1147-50.
12. Guitart J, Lowe L, Peipkorn M, Prieto VG, Rabkin MS, Ronan SG, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002;138:603-8.
13. Mansson-Brahme E, Carstensen J, Erhardt K, Lagerlof B, Ringborg U, Rutqvist LE. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994;73:2324-32.
14. Houghton AN, Bloomer WD, Chu D, Coit DG, Eisenberg BL, Guitart J, et al. The NCCN Melanoma Cancer clinical practice guidelines in oncology, version 1.2002. Available at: http://www.nccn.org/physician_gls/index.html. Accessed Jan 27, 2003. To view the most recent version of the guideline, go online to www.nccn.org
15. Houghton AN, Bloomer WD, Chu D, Coit DG, Eisenberg BL, Guitart J, et al. The NCCN Melanoma Cancer clinical practice guidelines in oncology, version 1.2002. Available at: http://www.nccn.org/physician_gls/index.html. Accessed Jan 27, 2003. To view the most recent version of the guideline, go online to www.nccn.org
16. Albert VA, Koh HK, Bellar AC, Miller DR, Prout MN, Lew RA. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 1990;23:308-10.
17. Reintgen DS, Cox EB, McCarty KS, Vollmer RT, Seigler HF. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983;198:379-85.
18. McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet 1985;161: 575-80.
19. Shen P, Guenther JM, Wanek LA, Morton DL. Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences? Ann Surg Oncol 2000;7:114-9.
20. McCarthy WH, Shaw HM, McCarthy SW, River JK, Thompson JF. Cutaneous melanomas that defy conventional prognostic indicators. Semin Oncol 1996;23:709-13.
21. Lyman GH, Kuderer NM, Balducci L. Cost-benefit analysis of colony-stimulating factor in the management of elderly cancer patients. Curr Opin Hematol 2002;9:207-14.
22. Heyland DK, Gafni A, Kernerman P, Keenan S, Chalfin D. How to use the results of an economic evaluation. Crit Care Med 1999;27:1195-202.
23. Provenzale D. Cost-effectiveness of screening the average-risk population for colorectal cancer. Gastrointest Endosc Clin N Am 2002;12:93-109.